Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast Cancer

Purpose: We have evaluated the eukaryotic translation initiation factor 4E (eIF4E) as a potential biomarker and therapeutic target in breast cancer. eIF4E facilitates nuclear export and translation of specific, growth-stimulatory mRNAs and is frequently overexpressed in cancer. Experimental Design: Breast cancer cells were treated with ribavirin, an inhibitor of eIF4E, and effects on cell proliferation and on known mRNA targets of eIF4E were determined. eIF4E expression was assessed, at the mRNA and protein level, in breast cancer cell lines and in skin biopsies from patients with metastatic disease. Additionally, pooled microarray data from 621 adjuvant untreated, node-negative breast cancers were analyzed for eIF4E expression levels and correlation with distant metastasis–free survival (DMFS), overall and within each intrinsic breast cancer subtype. Results: At clinically relevant concentrations, ribavirin reduced cell proliferation and suppressed clonogenic potential, correlating with reduced mRNA export and protein expression of important eIF4E targets. This effect was suppressed by knockdown of eIF4E. Although eIF4E expression is elevated in all breast cancer cell lines, variability in ribavirin responsiveness was observed, indicating that other factors contribute to an eIF4E-dependent phenotype. Assessment of the prognostic value of high eIF4E mRNA in patient tumors found that significant discrimination between good and poor outcome groups was observed only in luminal B cases, suggesting that a specific molecular profile may predict response to eIF4E-targeted therapy. Conclusions: Inhibition of eIF4E is a potential breast cancer therapeutic strategy that may be especially promising against specific molecular subtypes and in metastatic as well as primary tumors. Clin Cancer Res; 17(9); 2874–84. ©2011 AACR.

[1]  Correction: Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast Cancer , 2011, Clinical Cancer Research.

[2]  K. Borden,et al.  Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond? , 2010, Leukemia & lymphoma.

[3]  K. Shokat,et al.  Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. , 2010, Cancer cell.

[4]  Robert L Sutherland,et al.  PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality , 2010, International journal of cancer.

[5]  B. Leber,et al.  Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. , 2009, Blood.

[6]  R. Greil,et al.  Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[8]  S. Sleijfer,et al.  The applicability of mTOR inhibition in solid tumors. , 2009, Current cancer drug targets.

[9]  V. Speirs,et al.  Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity , 2009, British Journal of Cancer.

[10]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Gao,et al.  Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells , 2009, Breast Cancer Research and Treatment.

[12]  T. Hoang,et al.  Stability of Eukaryotic Translation Initiation Factor 4E mRNA Is Regulated by HuR, and This Activity Is Dysregulated in Cancer , 2008, Molecular and Cellular Biology.

[13]  Emmanuel Barillot,et al.  Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells , 2008, Breast Cancer Research.

[14]  K. Borden,et al.  Ribavirin targets eIF4E dependent Akt survival signaling. , 2008, Biochemical and biophysical research communications.

[15]  C. Meschonat,et al.  A Prospective Trial on Initiation Factor 4E (eIF4E) Overexpression and Cancer Recurrence in Node-Negative Breast Cancer , 2008, Annals of Surgical Oncology.

[16]  Gopal Singh,et al.  eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling , 2008, Molecular Cancer Therapeutics.

[17]  K. Borden,et al.  The eIF4E RNA regulon promotes the Akt signaling pathway , 2008, The Journal of cell biology.

[18]  N. Sonenberg.  eIF4E, the mRNA cap-binding protein: from basic discovery to translational research. , 2008, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[19]  J. Graff,et al.  Targeting the eukaryotic translation initiation factor 4E for cancer therapy. , 2008, Cancer research.

[20]  Tao Wang,et al.  Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. , 2007, The Journal of clinical investigation.

[21]  O. Larsson,et al.  Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. , 2007, Cancer research.

[22]  K. Borden,et al.  Controlling Gene Expression through RNA Regulons: The Role of the Eukaryotic Translation Initiation Factor eIF4E , 2007, Cell cycle.

[23]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[24]  K. Borden,et al.  eIF4E is a central node of an RNA regulon that governs cellular proliferation , 2006, The Journal of cell biology.

[25]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[26]  C. Meschonat,et al.  High eIF4E, VEGF, and Microvessel Density in Stage I to III Breast Cancer , 2006, Annals of surgery.

[27]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[28]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[29]  C. Meschonat,et al.  Detection of eIF4E gene amplification in breast cancer by competitive PCR , 1998, Annals of Surgical Oncology.

[30]  K. Borden,et al.  Homeodomain proteins and eukaryotic translation initiation factor 4E (eIF4E): an unexpected relationship. , 2005, Histology and histopathology.

[31]  F. Khuri,et al.  Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. , 2005, Cancer research.

[32]  Wolfgang Eiermann,et al.  Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  K. Borden,et al.  eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3′UTR , 2005, The Journal of cell biology.

[34]  H. Joensuu,et al.  Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. , 2005, Cancer research.

[35]  N. Sonenberg,et al.  Regulation of cap-dependent translation by eIF4E inhibitory proteins , 2005, Nature.

[36]  A. Kentsis,et al.  Eukaryotic Translation Initiation Factor 4E Activity Is Modulated by HOXA9 at Multiple Levels , 2005, Molecular and Cellular Biology.

[37]  A. Kentsis,et al.  Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  W. Miller,et al.  Enhanced retinoid-induced apoptosis of MDA-MB-231 breast cancer cells by PKC inhibitors involves activation of ERK , 2004, Oncogene.

[39]  N. Sonenberg,et al.  Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. , 2004, Cancer cell.

[40]  K. Borden,et al.  The emerging roles of translation factor eIF4E in the nucleus. , 2002, Differentiation; research in biological diversity.

[41]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[42]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  A. Kentsis,et al.  PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA , 2001, The EMBO journal.

[44]  A. Namboodiri,et al.  Transcriptional regulation of the rat eIF4E gene in cardiac muscle cells: the role of specific elements in the promoter region. , 2001, Gene.

[45]  N. Sonenberg,et al.  A novel shuttling protein, 4E‐T, mediates the nuclear import of the mRNA 5′ cap‐binding protein, eIF4E , 2000, The EMBO journal.

[46]  A. De Benedetti,et al.  Antisense RNA to eIF4E Suppresses Oncogenic Properties of a Head and Neck Squamous Cell Carcinoma Cell Line , 2000, The Laryngoscope.

[47]  A. Gingras,et al.  4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. , 1998, Genes & development.

[48]  A. De Benedetti,et al.  The proto‐oncogene/translation factor eIF4E: A survey of its expression in breast carcinomas , 1995, International journal of cancer.

[49]  J. Russo,et al.  Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. , 1990, Cancer research.